University of Texas Technology Initiated for Clinical Trials for Cellulite Treatment in Humans

Medical device venture Soliton Inc. (NASDAQ: SOLY) has been approved from Institutional Review Board (IRB) to study a proprietary platform technology licensed to them from the University of Texas on behalf of MD Anderson Cancer Center. The study has been initiated after positive preclinical results indicated the potential for a higher energy form of acoustic shockwave technology to affect the factors contributing to the formation of cellulite. Soliton’s CEO noted “our preclinical data led us to believe we could have a significant impact on the reduction cellulite.”